Total Payments
$5,561
2024 Payments
$413.72
Companies
30
Transactions
87
Medicare Patients
8,517
Medicare Billing
$3.1M
Payment Breakdown by Category
Other$3,225 (58.0%)
Food & Beverage$2,166 (38.9%)
Education$169.98 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,375 | 3 | 42.7% |
| Food and Beverage | $2,166 | 76 | 38.9% |
| Honoraria | $850.00 | 1 | 15.3% |
| Education | $169.98 | 7 | 3.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,462 | 5 | $0 (2017) |
| PFIZER INC. | $1,069 | 13 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $321.43 | 11 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $247.95 | 9 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $148.31 | 2 | $0 (2018) |
| Amgen Inc. | $134.66 | 4 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $127.90 | 2 | $0 (2021) |
| Pharmacyclics LLC, An AbbVie Company | $124.99 | 1 | $0 (2017) |
| Kite Pharma, Inc. | $115.50 | 2 | $0 (2022) |
| Incyte Corporation | $99.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $413.72 | 15 | E.R. Squibb & Sons, L.L.C. ($123.37) |
| 2023 | $370.84 | 19 | PFIZER INC. ($136.44) |
| 2022 | $266.45 | 11 | Novartis Pharmaceuticals Corporation ($139.65) |
| 2021 | $215.24 | 4 | Janssen Pharmaceuticals, Inc ($102.62) |
| 2020 | $961.64 | 8 | PFIZER INC. ($853.95) |
| 2019 | $38.79 | 2 | E.R. Squibb & Sons, L.L.C. ($34.16) |
| 2018 | $287.10 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($148.31) |
| 2017 | $3,007 | 22 | AstraZeneca Pharmaceuticals LP ($2,462) |
All Payment Transactions
87 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $123.37 | General |
| 08/29/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $30.74 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.97 | General |
| Category: Hematology | ||||||
| 07/25/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: Immunology | ||||||
| 06/27/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.13 | General |
| 06/05/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $23.81 | General |
| 05/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.04 | General |
| Category: Oncology | ||||||
| 04/30/2024 | Medtronic, Inc. | OSTEOCOOL RF ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: Neuro Pain (includes Interventional) | ||||||
| 04/04/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Oncology | ||||||
| 03/21/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: ONCOLOGY | ||||||
| 02/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.34 | General |
| 02/08/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: ONCOLOGY | ||||||
| 01/10/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $19.22 | General |
| 12/13/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.91 | General |
| 11/30/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: Oncology | ||||||
| 11/02/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $24.79 | General |
| Category: Hematology | ||||||
| 09/21/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $17.51 | General |
| 09/08/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: Oncology | ||||||
| 08/24/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: Oncology | ||||||
| 08/10/2023 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: Oncology | ||||||
| 07/27/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Oncology | ||||||
| 06/28/2023 | PFIZER INC. | TALZENNA (Drug), XTANDI | Food and Beverage | In-kind items and services | $85.98 | General |
| Category: ONCOLOGY | ||||||
| 06/07/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $22.12 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 1,732 | 34,646 | $2.5M | $622,441 |
| 2022 | 46 | 2,060 | 53,044 | $3.6M | $823,847 |
| 2021 | 40 | 2,107 | 39,668 | $2.9M | $665,740 |
| 2020 | 47 | 2,618 | 52,638 | $4.2M | $987,255 |
Total Patients
8,517
Total Services
179,996
Medicare Billing
$3.1M
Procedure Codes
169
All Medicare Procedures & Services
169 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 15 | 10,200 | $1.4M | $441,283 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 123 | 430 | $158,240 | $40,393 | 25.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 23 | 25 | $120,050 | $27,730 | 23.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 14 | 10,440 | $208,800 | $24,620 | 11.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 51 | 183 | $129,381 | $18,010 | 13.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 171 | 263 | $65,750 | $14,965 | 22.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 248 | 1,015 | $20,300 | $8,526 | 42.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 245 | 971 | $34,956 | $7,389 | 21.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 203 | 622 | $39,808 | $6,438 | 16.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 42 | 203 | $31,871 | $4,403 | 13.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 12 | 78 | $16,458 | $4,278 | 26.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $19,775 | $4,023 | 20.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 34 | 67 | $20,971 | $3,090 | 14.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 21 | 54 | $18,576 | $2,573 | 13.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 27 | 27 | $10,044 | $2,047 | 20.4% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 21 | 22 | $14,454 | $1,981 | 13.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 12 | $5,952 | $1,607 | 27.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 16 | 57 | $9,177 | $1,217 | 13.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 30 | 113 | $10,848 | $1,180 | 10.9% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 23 | 46 | $4,324 | $828.92 | 19.2% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 43 | 61 | $3,660 | $814.96 | 22.3% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 19 | 6,900 | $34,500 | $776.35 | 2.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 22 | $3,190 | $564.27 | 17.7% |
| 83550 | Iron binding capacity | Office | 2023 | 44 | 60 | $2,100 | $514.20 | 24.5% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 12 | 89 | $38,359 | $472.92 | 1.2% |
About Dr. Daniel Farray-Berges, M.D
Dr. Daniel Farray-Berges, M.D is a Medical Oncology healthcare provider based in Weslaco, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639116288.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Farray-Berges, M.D has received a total of $5,561 in payments from pharmaceutical and medical device companies, with $413.72 received in 2024. These payments were reported across 87 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2,375).
As a Medicare-enrolled provider, Farray-Berges has provided services to 8,517 Medicare beneficiaries, totaling 179,996 services with total Medicare billing of $3.1M. Data is available for 4 years (2020–2023), covering 169 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Weslaco, TX
- Active Since 06/01/2006
- Last Updated 10/22/2008
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1639116288
Products in Payments
- TAGRISSO (Drug) $2,457
- OPDIVO (Biological) $185.42
- PROMACTA (Drug) $158.96
- NINLARO (Drug) $148.31
- Kyprolis (Biological) $134.66
- XARELTO (Drug) $127.90
- Imbruvica (Drug) $124.99
- Yescarta (Drug) $100.00
- XTANDI (Drug) $88.10
- TALZENNA (Drug) $85.98
- INLYTA (Drug) $81.12
- Lenvima (Drug) $67.94
- ADCETRIS (Biological) $57.81
- IBRANCE (Drug) $51.83
- DARZALEX (Biological) $47.34
- REBLOZYL (Biological) $39.76
- Cabometyx (Drug) $39.66
- TASIGNA (Drug) $29.34
- SCEMBLIX (Drug) $27.98
- OSTEOCOOL RF ABLATION SYSTEM (Device) $23.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.